摘要 |
<p>The present invention relates to a peptide having specific immunoreactivity to antibodies to HTLV-I, HTLV-II, or combinations thereof comprising a peptide selected from the group consisting of: Env-1 (HTLV-I; a.a 191-215)LPHSNLDHILEPSIPWKSKLLTLV, Env-2 (HTLV-II; a.a 187-210)VHDSDLEHVLTPSTSWTTKILKFI, Env5 (HTLV-I; a.a 242-257)SPNVSVPSSSSTPLLY, Gagla (HTLV-I; a.a 102-117)PPSSPTHDPPDSDPQI, Pol-3 (HTLV-I; a.a 487-502)KQILSQRSFPLPPPHK, Env-20 (HTLV-II; a.a. 85-102)KKPNRQGLGYYSPSYNDP, Env-23 (HTLV-I; a.a. 274-289)QPRLQAITTDNCNNSI, Gag-10 (HTLV-I/II; a.a. 364-285)GHWSRDCTQPRPPPGPCPLCQDP, Ers (endogenous retroviral sequence)PRIPPKPCPICVCPNWKSDCPT, and analogues thereof, wherein the amino acids in the sequence may be substituted as long as the immunoreactivity to antibodies to HTLV-I or HTLV-II derived from the three-dimensional conformation of the sequences are substantially preserved. The invention is further directed to an immunoassay method for the detection of antibodies to HTLV-I, HTLV-II or a combination thereof, a test kit for the detection of said antibodies, a peptide composition containing said peptides and a vaccine.</p> |